LEVERAGER Trademark

Trademark Overview

On Friday, May 27, 2022, a trademark application was filed for LEVERAGER with the United States Patent and Trademark Office. The USPTO has given the LEVERAGER trademark a serial number of 97432416. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, March 26, 2025. This trademark is owned by Fosun Pharma USA Inc.. The LEVERAGER trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug discovery services; Research and development in the field of design of RNA-targeted drugs
leverager

General Information

Serial Number97432416
Word MarkLEVERAGER
Filing DateFriday, May 27, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, March 26, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 21, 2023

Trademark Statements

Goods and ServicesDrug discovery services; Research and development in the field of design of RNA-targeted drugs

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 3, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameFosun Pharma USA Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08540
Party NameFosun Pharma USA Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08540

Trademark Events

Event DateEvent Description
Monday, December 5, 2022NON-FINAL ACTION E-MAILED
Tuesday, May 31, 2022NEW APPLICATION ENTERED
Friday, June 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 5, 2022ASSIGNED TO EXAMINER
Monday, December 5, 2022NON-FINAL ACTION WRITTEN
Monday, December 5, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 23, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 23, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, December 24, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 1, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 21, 2023PUBLISHED FOR OPPOSITION
Tuesday, February 21, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, October 13, 2023SOU EXTENSION 1 FILED
Friday, October 13, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 13, 2023SOU EXTENSION 1 GRANTED
Tuesday, October 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU EXTENSION 3 FILED
Monday, February 5, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 5, 2024SOU EXTENSION 2 FILED
Monday, February 5, 2024SOU EXTENSION 2 GRANTED
Wednesday, February 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU EXTENSION 3 GRANTED
Wednesday, March 26, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, March 26, 2025SOU EXTENSION 4 FILED
Wednesday, August 27, 2025SOU TEAS EXTENSION RECEIVED
Thursday, March 27, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 27, 2025SOU EXTENSION 4 GRANTED

Related Keywords

leverager design targeted drugs field development discovery services research drug